A discrete choice experiment to determine UK patient preference for attributes of disease modifying treatments in Multiple Sclerosis

Bottomley, Catherine; Lloyd, Andrew; Gary, Bennett; Adlard, Nicholas

doi:10.1080/13696998.2017.1336099

Cited by 26 publications

(45 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similar to prior literature, our model showed that patients with RRMS in the UK prefer oral DMDs and infusions relative to injections 22,23,27 , as well as DMDs with less frequent administration 26 . However, our results also showed that current DMD market shares within the UK RRMS population do not reflect these patient preferences.…”

Section: Discussionsupporting

confidence: 81%

“…This DCE was chosen because it is the most recent study we identified which measured the preferences of patients with RRMS in the UK. Further, the study had a larger sample size and was inclusive of more DMDs than previous DCEs in this therapeutic area 22,24 .…”

Section: Model Overviewmentioning

confidence: 99%

“…Given the expanding treatment options 21 , a large body of research has evolved around understanding patients' preferences for various attributes of DMDs [22][23][24][25][26][27] . These studies suggest that treatment frequency, mode of administration, and likelihood of side effects from a DMD are of importance to patients [25][26][27] .…”

Section: Introductionmentioning

confidence: 99%

“…These studies suggest that treatment frequency, mode of administration, and likelihood of side effects from a DMD are of importance to patients [25][26][27] . Studies show that patients strongly prefer oral administration 22,23,27 , particularly when oral treatment dosing is less frequent (e.g. less than three times daily) and the treatment has infrequent side effects 26 .…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Modeling the impact of patient treatment preference on health outcomes in relapsing-remitting multiple sclerosis

Eijndhoven¹,

Brauer²,

Kee³

et al. 2020

Journal of Medical Economics

View full text Add to dashboard Cite

Aims: Model how moving from current disease-modifying drug (DMD) prescribing patterns for relapsing-remitting multiple sclerosis (RRMS) observed in the United Kingdom (UK) to prescribing patterns based on patient preferences would impact health outcomes over time. Materials and methods: A cohort-based Markov model was used to measure the effect of DMDs on long-term health outcomes for individuals with RRMS. Data from a discrete choice experiment were used to estimate the market shares of DMDs based on patient preferences (i.e. preference shares). These preference shares and real-world UK market shares were used to calculate the effect of prescribing behavior on relapses, disability progression, and quality-adjusted life-years (QALYs). The incremental benefit of patient-centered prescribing over current practices for the UK RRMS population was then estimated; scenario and sensitivity analyses were also conducted. Results: Compared to current prescribing practices, when UK patients with RRMS were treated following patient preferences, health outcomes were improved. This population was expected to experience 501,690 relapses and gain 1,003,263 discounted QALYs over 50 years under patient-centered prescribing practices compared to 538,417 relapses and 958,792 discounted QALYs under current practices (À6.8% and þ4.6%, respectively). Additionally, less disability progression was observed when prescribed treatment was based on patient preferences. In a scenario analysis where only oral treatments were considered, the results were similar, although the magnitude of benefit was smaller. Number of relapses was most sensitive to how the annualized relapse rate was modeled; disability progression was most sensitive to mortality rate assumptions. Limitations: Treatment efficacy estimates applied to various models in this study were based on data derived from clinical trials, rather than real-world data; the impact of patient-centered prescribing on treatment adherence and/or switching was not modeled. Conclusions: The population of UK RRMS patients may experience overall health gains if patient preferences are better incorporated into prescribing practices.

show abstract

Section: Discussionsupporting

confidence: 81%

Section: Model Overviewmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Modeling the impact of patient treatment preference on health outcomes in relapsing-remitting multiple sclerosis

Eijndhoven¹,

Brauer²,

Kee³

et al. 2020

Journal of Medical Economics

View full text Add to dashboard Cite

show abstract

“…The literature indicates that patient preferences may not be in line with an appropriate treatment approach. Patients with longer disease duration prefer more efficacious therapies 42 and tend to underestimate therapy risks and overestimate benefits. 43 This approach may be counter to disease biology, which likely benefits from the use of higher efficacy agents earlier in the disease.…”

Section: The Reported Safety Profiles Of Some Highly Effective Agentsmentioning

confidence: 99%

An argument for broad use of high efficacy treatments in early multiple sclerosis

Stankiewicz

Weiner

2020

Neurol Neuroimmunol Neuroinflamm

View full text Add to dashboard Cite

Two different treatment paradigms are most often used in multiple sclerosis (MS). An escalation or induction approach is considered when treating a patient early in the disease course. An escalator prioritizes safety, whereas an inducer would favor efficacy. Our understanding of MS pathophysiology has evolved with novel in vivo and in vitro observations. The treatment landscape has also shifted significantly with the approval of over 10 new medications over the past decade alone. Here, we re-examine the treatment approach in light of these recent developments. We believe that recent work suggests that early prediction of the disease course is fraught, the amount of damage to the brain that MS causes is underappreciated, and its impact on patient function oftentimes is underestimated. These concerns, coupled with the recent availability of agents that allow a better therapeutic effect without compromising safety, lead us to believe that initiating higher efficacy treatments early is the best way to achieve the best possible long-term outcomes for people with MS. Multiple sclerosis following collection(s):This article, along with others on similar topics, appears in the Permissions & Licensing http://nn.neurology.org/misc/about.xhtml#permissions its entirety can be found online at: Information about reproducing this article in parts (figures,tables) or in Reprints http://nn.neurology.org/misc/addir.xhtml#reprintsus Information about ordering reprints can be found online: Academy of Neurology.. All rights reserved. Online

show abstract

Identifying DCE Attributes and Levels

Shang,

Chandra

2023

Discrete Choice Experiments Using R

View full text Add to dashboard Cite

A discrete choice experiment to determine UK patient preference for attributes of disease modifying treatments in Multiple Sclerosis

Abstract: These results, derived from people with MS in the UK, should be used to inform individual discussions with patients about DMT choices.

Cited by 26 publications

References 21 publications

Modeling the impact of patient treatment preference on health outcomes in relapsing-remitting multiple sclerosis

Modeling the impact of patient treatment preference on health outcomes in relapsing-remitting multiple sclerosis

An argument for broad use of high efficacy treatments in early multiple sclerosis

Identifying DCE Attributes and Levels

Contact Info

Product

Resources

About